Smartlab Europe

FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Taiwan Launches $755M Pharma Resilience Plan to Boost Supply

Taiwan is preparing a four-year national pharmaceutical resilience preparedness...

Norgine Invests £23m to Expand Hengoed Pharma Facility in UK

Norgine has confirmed a £23 million ($31 million) investment...

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...
- Advertisement -

Dr. Reddy’s Laboratories announced that it will be launching Lansoprazole delayed-release capsules (15 mg and 30 mg), a bioequivalent generic version of Prevacid®* Delayed-Release Capsules, in the US market. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules on October 15, 2010. Launch preparations are complete and shipments will commence shortly. Dr. Reddy’s Lansoprazole delayed-release capsules are available in bottles of 30 & 90 counts in 15mg and 90 and 500 counts in 30 mg.

 

Latest stories

Related stories

Taiwan Launches $755M Pharma Resilience Plan to Boost Supply

Taiwan is preparing a four-year national pharmaceutical resilience preparedness...

Norgine Invests £23m to Expand Hengoed Pharma Facility in UK

Norgine has confirmed a £23 million ($31 million) investment...

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...

Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal

Sanofi has committed up to $1.53 billion to obtain...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »